Cure My Disease

Don't miss your cure!

 Log in / Sign up

A 3-Second memory test could flag early decline

NCT ID NCT01123018

Diagnosis Sponsor: John Wesson Ashford Jr Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 26, 2026 · Last updated Aug 27, 2026 · Updated 1 time

Summary

This trial is testing a simple memory screening tool called MemTrax, which involves recognizing repeated images. The goal is to see if this quick test can identify people with memory problems and refer them to more detailed memory studies. Adults aged 21 and older without major psychiatric or medical issues may participate. The test measures memory hits and response speed to flag potential impairment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Memtrax memory screening test (a behavioral test)
What this could lead to
If this screening test proves reliable, it could help identify people with early memory problems and connect them to appropriate research studies.
What could go wrong
This is a very small screening study, not a treatment trial. The test may not be accurate for everyone, and it is not a diagnostic tool for dementia or Alzheimer's disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1 person

The number who actually took part.

Start date

Jun 2007

Finished

Dec 2023

Lead sponsor

A government agency

The lead sponsor is a US federal agency other than the NIH.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

healthy older adults with memory concerns

Ages

21 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 21 or over. Exclusion Criteria: * Major psychiatric problems. * Major medical problems. * Aversion to test-taking.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease dementia Memory Disorders

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alzheimer disease Dementia Memory deficits Memory loss

Contacts and locations

Locations

  • VA Palo Alto Health Care System

    Palo Alto, California, 94304, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.